Loading
Life sciences · Journal article
Frontiers in Bioengineering and Biotechnology · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Programmed cell death ligand 1 (PD-L1) antibody has been shown to hold tremendous promise in curing metastatic colorectal cancer (CRC). However, the delivery efficacy of the targeted biologics limits this immunotherapy in a subset of CRC. Here we report a novel biomimetic ‘Trojan horse’ nano-delivery system for targeted gene-immunotherapy of colorectal cancer. The system comprises a core of gold nanoparticles and cationic liposomes encapsulating CRISPR/Cas9–sgSOX9, camouflaged with homologous CRC cell membranes for immune evasion and tumor tropism, and functionalized with PD-L1 antibodies to enhance tumor recognition and relieve immune suppression. In vitro, the nano-system potently suppressed CRC cell proliferation, migration and invasion. in vivo, it exhibited robust tumor-targeting specificity, favorable preliminary biosafety profile and marked inhibition of tumor growth in subcutaneous xenograft models. Mechanistically, the system remodeled the tumor microenvironment by promoting CD8 + T-cell infiltration and elevating effector cytokines IFN-γ and TNF-α. By seamlessly coupling precise gene delivery with potent immune activation, this nanoplatform offers a compelling therapeutic strategy for colorectal cancer therapy.